The device has passed all validation tests prior to use with Covid-19 patients and electromagnetic compatibility tests, so that it currently has authorization from the Spanish Agency for Medicines and Health Products (AEMPS) of the Ministry of Health from Spain for use in hospitals as a clinical study, allowing its effective use with Covid-19 patients.

The RESPIRA project has been developed under the supervision of the Catalan Institute of Health (ICS) of the Generalitat of Catalonia and with the participation of the Hospital Clínic de Barcelona and the Center for Comparative Medicine and Bioimatge of the Germans Trias and Pujol Research Institute - Can Ruti de Badalona , and also has the collaboration of health workers from the Hospital de Sant Joan de Déu in Barcelona .

Developed together with

With the collaboration and participation of our partners

C/Caracas 13-15 Nau 6

08030  Barcelona, Spain

info@gpainnova.com

Tel: +34 931 256 536

Fax: +34 934 318 271

a product of

Follow us at

  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • YouTube

@Gpainnova

#RESPIRA

#GPAINNOVA

WARNING: Although we are working on the CE certification and conformity of the RESPIRA device, it does not satisfy the legal requirements of the EU yet. Therefore, the RESPIRA device is nowadays a product not destined for the European Union market and it is not intended to come onto EU market or to be placed in service in the EU until it meets the EU legal requirements.

RESPIRAdevice.com © 2020 

WARNING: Although we are working on the CE certification and conformity of the RESPIRA device, it does not satisfy the legal requirements of the EU yet. Therefore, the RESPIRA device

is nowadays a product not destined for the European Union market and it is not intended to come onto EU market or to be placed in service in the EU until it meets the EU legal requirements.